Free Trial
→ $0. Later: $29.97. (From Profits Run) (Ad)tc pixel
NASDAQ:CGON

CG Oncology Q4 2025 Earnings Results & Report

CG Oncology logo
$71.23 +1.08 (+1.54%)
As of 12:25 PM Eastern
This is a fair market value price provided by Massive. Learn more.

CG Oncology beat analyst earnings expectations in its Q4 2025 results, released February 27, 2026. The company reported EPS of -$0.51 versus the -$0.61 consensus estimate, while revenue was $2.32 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens
Conference Call
8:30 AM ET

CG Oncology EPS Results

Actual EPS
-$0.51
Consensus EPS
-$0.61
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

CG Oncology Revenue Results

Actual Revenue
$2.32 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

CG Oncology's Q4 2025 Press ReleasePress Release
(8-K)
CG Oncology's Q4 2025 Annual reportAnnual report
(10-K)

CG Oncology Q4 2025 Earnings FAQ

CG Oncology (NASDAQ:CGON) reported earnings of -$0.51 per share for Q4 2025, beating the consensus estimate of -$0.61. The report was announced on Friday, February 27, 2026.

CG Oncology reported revenue of $2.32 million for Q4 2025.

CG Oncology Earnings Headlines

CG Oncology FY2026 Earnings Forecast Lifted by HC Wainwright
November 12 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31193243
CG Oncology (NASDAQ:CGON) Stock Price Target Cut by Guggenheim
November 11 at 2:51 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31191413
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
November 13 at 1:00 AM  |  Base Camp Trading (Ad)
What CG Oncology (CGON)'s Third Quarter Earnings Means For Shareholders
November 10 at 3:37 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/cg-oncology-cgon-third-quarter-130913745.html
CG Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026
November 6, 2026  |  marketscreener.comM
CG Oncology Gains on Q3 Results
November 6, 2026  |  baystreet.cahttps://www.baystreet.ca/stockstowatch/24348/CG-Oncology-Gains-on-Q3-Results
See More CG Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CG Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CG Oncology and other key companies, straight to your email.

About CG Oncology

CG Oncology (NASDAQ:CGON) is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder.

Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.

CG Oncology has no approved commercial products. Its clinical development program includes studies of cretostimogene alone and in combination with other cancer treatments. The company is led by President and Chief Executive Officer Arthur Kuan.

View CG Oncology Profile
Earnings Tools